Antares Pharma, Inc. (ATRS)

[hyperopia]

In an interview at ASCO, the chief development officer for Pfizer Oncology, Chris Boshoff, said something of interest that may portend good news to Antares investors:

“Why are we developing another checkpoint? The current checkpoints are essentially all being developed as intravenous infusion. This one is being developed specifically only as a subcutaneous administration, so it will be a prefilled syringe. The current regimen is once every four weeks, but our [pharmacokinetic] data indicates we potentially can go once every six weeks. Having a subcutaneous, prefilled syringe as a backbone to targeted therapies we feel could optimize the way we develop immune checkpoints in the future.”

I’m not speculating that Pfizer is going to contract with Anares for this, since Pfizer is building their own state-of-the-art sterile injectable pharmaceutical production facility in Michigan, but it indicates where the industry is headed and that Antares’ expertise is likely to be in very high demand.


https://www.biopharmadive.com/news/asco-19-pfizer-immunotherapy-targeted-cancer-drugs/556067/